Pharma companies directory 2026
Pharmaceutical Companies in Nigeria
Estimates of the local share of supply diverge sharply, from the Pharmaceutical Society’s view that more than 70% of medicines are imported to the manufacturers’ group’s claim that essential medicines are now roughly half locally made, because value, volume and product type are being measured differently. What is not disputed is that the industrial base is expanding: NAFDAC’s five-plus-five registration rule obliges foreign brand owners to plan local production, over a hundred functional plants operate in Lagos, Ogun, Anambra and Enugu, and Fidson, May & Baker, Mecure and Neimeth trade on the Nigerian Exchange. Multinationals have restructured in the opposite direction, with GSK and Sanofi closing their Lagos affiliates in 2023 in favour of third-party distributors, while Pfizer, Novartis and Roche kept commercial teams. Naira devaluation has raised the cost of imported brands and pushed prescribers toward domestic generics and Indian imports. This directory lays out the manufacturers, remaining affiliates, importers and the regulator that together define competition in each therapy area.
Updated September 2026 · National Agency for Food and Drug Administration and Control (NAFDAC) — registered products and licensed manufacturers as of September 2026 · 21 named accounts
$2.7bn
Nigerian pharmaceutical market value in 2024 (estimates range from $2bn to $3.3bn)
120+
Functional local pharmaceutical manufacturers operating in Nigeria
~50%
Share of essential-medicine demand met by domestic production, per PMG-MAN, 2025
4
Pharmaceutical manufacturers listed on the Nigerian Exchange after GSK’s 2023 exit
Named accounts
Top pharmaceutical companies in Nigeria
| # | Company | HQ | Type | Therapeutic focus | Notes |
|---|---|---|---|---|---|
| 01 | Emzor Pharmaceutical Industries | Lagos | Local | ||
| 02 | Fidson Healthcare | Lagos | Local | ||
| 03 | May & Baker Nigeria | Lagos | Local | ||
| 04 | Swipha (Swiss Pharma Nigeria) | Lagos | MNC | ||
| 05 | Neimeth International Pharmaceuticals | Lagos | Local | ||
| 06 | Juhel Nigeria | Enugu | Local | ||
| 07 | Orange Drugs | Lagos | Local | ||
| 08 | Mecure Industries | Lagos | Local | ||
| 09 | Drugfield Pharmaceuticals | Sango-Ota | Local | ||
| 10 | Chi Pharmaceuticals | Lagos | Local | ||
| 11 | Codix Pharma | Lagos | Local | ||
| 12 | Bond Chemical Industries | Awe, Oyo State | Local | ||
| 13 | Dana Pharmaceuticals | Minna | Local | ||
| 14 | Pfizer Nigeria | Lagos | MNC | ||
| 15 | Novartis Nigeria | Lagos | MNC | ||
| 16 | Roche Products Nigeria | Lagos | MNC | ||
| 17 | Ranbaxy Nigeria (Sun Pharma) | Lagos | MNC | ||
| 18 | Vitabiotics Nigeria | Lagos | MNC | ||
| 19 | Greenlife Pharmaceuticals | Lagos | Distributor | ||
| 20 | Worldwide Healthcare | Lagos | Distributor | ||
| 21 | National Agency for Food and Drug Administration and Control (NAFDAC) | Abuja | Government |
Primary research
These are the pharmaceutical companies accounts we study in Nigeria
Need account-level or SKU-level data for a brand in Nigeria? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.
Planning research in Nigeria?
Primary research, market access & HEOR. Proposals within 48 hours.
How the market is structured
How pharmaceutical companies operate in the Nigerian market
Local
Nigerian-owned manufacturers, several listed in Lagos, that formulate antimalarials, antibiotics, analgesics and infusions from imported inputs and dominate the general trade and state tenders.
- Emzor Pharmaceutical Industries
- Fidson Healthcare
- May & Baker Nigeria
- Neimeth International Pharmaceuticals
- Juhel Nigeria
- Orange Drugs
- Mecure Industries
- Drugfield Pharmaceuticals
- Chi Pharmaceuticals
- Codix Pharma
- Bond Chemical Industries
- Dana Pharmaceuticals
Multinational
Innovator and Indian-origin affiliates that kept Lagos commercial teams after GSK and Sanofi withdrew, concentrating on vaccines, oncology, specialty care and branded generics.
- Swipha (Swiss Pharma Nigeria)
- Pfizer Nigeria
- Novartis Nigeria
- Roche Products Nigeria
- Ranbaxy Nigeria (Sun Pharma)
- Vitabiotics Nigeria
Regional
West African and pan-African groups that treat Nigeria as the anchor of an ECOWAS portfolio, typically importing through Lagos and serving Ghana and francophone markets from the same base.
Distributors & importers
Importer-marketers that hold registrations for foreign brands, the wholesalers of the open drug markets, and the federal regulator whose policies decide who may sell what.
- Greenlife Pharmaceuticals
- Worldwide Healthcare
- National Agency for Food and Drug Administration and Control (NAFDAC)
What is moving
What is moving the pharmaceutical market in Nigeria
NAFDAC five-plus-five and Executive Order incentives
The registration rule that forces localisation, combined with 2024 duty and VAT waivers on pharmaceutical inputs, has triggered eleven new plant commissionings scheduled for 2026 and a wave of contract-manufacturing partnerships between importers and local plants.
Naira devaluation and import substitution
Successive currency adjustments since 2023 roughly tripled the naira cost of imported brands, shifting prescribing toward domestic generics and giving listed manufacturers their strongest revenue growth in a decade.
Health insurance expansion under the NHIA Act
The 2022 law making health insurance mandatory and creating state schemes is slowly enlarging the reimbursed formulary, which favours companies with registered generics on the essential medicines list and reliable supply records.
Coordinated wholesale centres and organised retail
Relocation of open drug markets into regulated wholesale centres, together with the expansion of HealthPlus, Medplus and other pharmacy chains, is professionalising the trade and rewarding brands with traceability and consistent availability.
BioNixus fieldwork
How BioNixus studies pharmaceutical companies in Nigeria
- Prescriber preference studies among consultants at Lagos University Teaching Hospital, UCH Ibadan, UNTH Enugu and Abuja hospitals comparing local generics with imported brands.
- Open-market wholesaler and pharmacy purchase audits in Idumota, Onitsha and Kano to estimate brand share and identify parallel-import leakage.
- Tender landscaping for state drug management agencies and federal teaching hospitals covering antimalarials, antibiotics, infusions and oncology awards.
- HMO and NHIA formulary interviews assessing reimbursement prospects for new generics and specialty products under the mandatory insurance framework.
Questions
Frequently Asked Questions
Which are the largest pharmaceutical companies in Nigeria?
By manufacturing scale and revenue the front rank includes Emzor, Fidson, May & Baker, Swipha, Neimeth, Juhel and Mecure, alongside multinational affiliates such as Pfizer and Novartis. Precise shares are hard to verify because most companies are privately held.
Why did GSK and Sanofi leave Nigeria?
Both cited currency scarcity, repatriation difficulties and a preference for distributor-led models; they now supply Nigeria through third-party importers rather than through their own Lagos affiliates.
What is NAFDAC’s five-plus-five policy?
A rule under which imported products receive an initial five-year registration but must show verifiable plans for local manufacture or partnership before renewal. It is intended to push foreign brand owners toward Nigerian production.
How do Nigerian hospitals buy medicines?
Federal teaching hospitals run their own tenders and drug revolving funds, many states procure through drug management agencies, and private and mission hospitals buy from wholesalers or directly from manufacturers. There is no single national public buyer.
How does BioNixus study pharmaceutical companies in Nigeria?
Through prescriber and pharmacist interviews in Lagos, Abuja, Port Harcourt, Kano and Enugu, audits of pharmacy and wholesaler purchase records in the open markets, tender-award mapping across federal and state institutions, and HMO formulary interviews.
Does the order of this Nigerian list indicate size?
No ranking is implied. Companies are grouped by ownership type and were selected because they recur in BioNixus Nigeria projects and on NAFDAC and Nigerian Exchange records.
Sources
Data sources & methodology
This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Nigeria. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.
Primary register: National Agency for Food and Drug Administration and Control (NAFDAC) — registered products and licensed manufacturers, consulted 2026-09-03. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Nigeria, not size.
- Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria (PMG-MAN) local production statements, 2025–2026
- KPMG Nigeria, Repositioning Nigeria’s Pharmaceutical Industry, 2026
- Nigerian Exchange annual reports for Fidson Healthcare, May & Baker, Mecure Industries and Neimeth, 2024–2025
- BioNixus Nigeria prescriber, pharmacy and open-market fieldwork, 2023–2026
BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.
48-hour proposal
Need brand and competitor data in Nigeria?
Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.
Planning research in Nigeria?
Primary research, market access & HEOR. Proposals within 48 hours.